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izard Spit
nd Reperfusion Injury*
an G. Webb, BMBCH, MRCP,
upert Williams, MB, BS,
ichael S. Marber, FRCP, FACC, PHD
ondon, United Kingdom
lthough the incidence of ST-segment elevation myocar-
ial infarction (STEMI) is declining in industrialized na-
ions, there are still an estimated 500,000 events annually in
he U.S. (1). Furthermore, the in-hospital mortality is 6% to
%, and over 15% of survivors to discharge experience a
ecurrent cardiovascular event by 6 months (2). Infarct size
s the key determinant of outcome, and prompt reperfusion
f the occluded epicardial artery is imperative to reduce
nfarction volume and improve mortality and morbidity.
aradoxically, however, reperfusion seems to contribute to
dditional myocardial damage over and above that caused by
he original ischemic insult. This additional damage is
nown as reperfusion injury and if it could be prevented an
lready exemplary treatment would be further improved.
See page 501
The concept of reperfusion injury has been recognized
nd its existence debated for over 30 years (3). At the
ellular level there are a variety of associated/causative
athophysiological processes, including oxidative stress, in-
racellular calcium dysregulation, inflammation, and rapid
ormalization of intracellular pH (4). Animal models sug-
est that reperfusion injury might contribute up to 50% of
ltimate infarction volume (4), and therefore its prevention
hould improve outcome. Unfortunately, despite numerous
nterventions showing promise in preclinical studies, very
ew have proved effective in clinical trials, and none has yet
mpacted on routine clinical practice (4,5).
In this issue of the Journal, Timmers et al. (6) present
ata in which the incretin mimetic exenatide significantly
educes myocardial infarction and improves left ventricular
LV) contraction and relaxation when it is given at reper-
usion. These findings gain clinical relevance and immedi-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.p
From King’s College London BHF Centre, Cardiovascular Division, The Rayne
nstitute, St. Thomas’ Hospital, London, United Kingdom.cy through the use of an approved drug, a large animal
odel, and the assessment of infarction after a long duration
f reperfusion.
Exenatide (sold commercially as “Byetta,” Amylin-Lilly,
an Diego, California) is currently licensed for parenteral
se as an adjunctive therapy in patients with poorly con-
rolled type II diabetes. Exenatide is a synthetic analogue of
xendin-4, also known as “lizard spit” and found in the
alivary secretions of the Gila monster, Heloderma suspectum
7). This 39-residue reptilian peptide is pharmacologically
imilar to mammalian glucagon-like peptide (GLP)-1 with
hich it shares 53% of its primary amino acid sequence
7,8). The GLP-1 is a gut-derived incretin hormone that is
ecreted by the intestine in response to nutrients. Like
LP-1, exenatide’s glucoregulatory effects are mediated
hrough a number of different mechanisms, including
ugmentation of glucose-stimulated insulin secretion
hence with low risk of a hypoglycemic overshoot),
uppression of postprandial glucagon secretion, delayed
astric emptying, and hypothalamic-mediated satiety of
ppetite (9). These actions are thought to be mediated via
he GLP-1 receptor present in the gastrointestinal tract,
ancreas, lung, kidney, brain, and heart (10).
Importantly, exenatide lacks the alanine residue found at
osition 2 of GLP-1 that directs its degradation. Conse-
uently, exenatide has a very much longer plasma half-life
han GLP-1 (approximately 2.4 h vs. 1 to 4 min). The
lanine-directed endopeptidase predominantly responsible
or the breakdown of GLP-1 is dipeptidyl peptidase (DPP)-
V. Thus, orally available inhibitors of DPP-IV increase the
alf-life of GLP-1 and are licensed similarly to exenatide for
he treatment of type II diabetes.
Exenatide/exendin-4 and GLP-1 are known to have a
umber of cardiovascular effects. In isolated perfused rat
earts exendin-4 reduced infarct size when administered at
eperfusion (11). This effect was abrogated by co-
dministration of a GLP-1 receptor antagonist. However,
he positive inotropic effect of exendin-4 was independent
f the GLP-1 receptor (11). Such GLP-1 receptor-
ndependent effects are expected, because exendin-4 is not a
rue reptilian homologue of GLP-1 (8).
Experiments in both isolated and in vivo rat hearts
uggest that GLP-1 significantly attenuates reperfusion
njury and reduces infarct size by approximately 50% when
oadministered with a DPP-IV inhibitor (12). The GLP-1
eems equally protective when given before lethal ischemia
s a preconditioning agent (13). In a model of sub-lethal
schemic injury, a 24-h intravenous infusion of GLP-1 after
10-min circumflex coronary artery occlusion in the dog
iminished stunning independent of alterations in systemic
emodynamic status and contractile function in the remote
yocardium (14).
The GLP-1 also exerts important effects on the failing
eart; a 48-h infusion of GLP-1 in a canine-model of
acing-induced cardiomyopathy resulted in enhanced myo-
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Incretins at Reperfusion February 10, 2009:511–3ardial insulin sensitivity and contractility (15). More re-
ently, chronic subcutaneous GLP-1 over 3 months in a rat
odel of hypertension-related heart failure improved myo-
ardial glucose uptake and reduced myocyte apoptosis,
ontractile dysfunction, and group mortality from 66% to
8% (16).
These observations have begun to be translated into
mall, nonrandomized, pilot clinical studies. A 5-week
ontinuous subcutaneous GLP-1 infusion in 12 patients
ith ejection fractions 40% and New York Heart Asso-
iation functional class III to IV symptoms was associated
ith significant improvements in objective measures of LV
unction and symptoms in both diabetic and nondiabetic
atients (17). A 48-h perioperative infusion of GLP-1 in
atients with preserved LV function undergoing elective
ypass surgery significantly reduced inotrope requirements
nd improved glycemic control in the immediate postoper-
tive period (18). An open, nonrandomized, pilot study has
ven examined the role of GLP-1 in patients with STEMI
eperfused by primary percutaneous coronary intervention.
leven such patients with impaired LV systolic function
LVEF 40%) received a 72-h GLP-1 infusion starting on
verage 212 min after the onset of reperfusion (19). Despite
his delay, the limited number of observations and an
chocardiographic end point, GLP-1 significantly improved
ecovery of LVEF and regional/global wall motion com-
ared with the 10 control subjects (19).
The data from Timmers et al. in this issue of the Journal
6) add further support to the cardioprotective effects of
ncretin analogues in a clinically applicable model of
schemia-reperfusion. The observed reduction in infarction
32.7% vs. 53.6%, p  0.03) with exenatide is impressive
nd accompanied by improvements in systolic and diastolic
unction as measured by echocardiography and invasive
imultaneous measurement of LV pressure and volume.
hese end points were collected after 3 days of reperfusion,
ffectively excluding a false-positive finding resulting from
he delay rather than the prevention of reperfusion injury,
lthough it could be argued that the results are predictable
n the basis of the findings with GLP-1 summarized in the
receding text. As already mentioned exenatide is not a true
LP-1 homologue (8). Furthermore, unlike GLP-1, its
alf-life allowed administration twice daily rather than by
ontinuous infusion.
The authors are to be congratulated on a well-designed
nd highly translational study; however, mechanistic insight
s still limited. Exenatide resulted in a significant increase in
hosphorylated (active) Akt at 2 h, a reduction in pro-
poptotic caspase-3 at 4 h, and higher levels of anti-
poptotic Bcl-2 and reduced oxidative stress at 72 h of
eperfusion. However, it is not clear whether any of these
ffects are causally related to protection. Furthermore, it is
ot clear whether it is the exenatide itself and/or the
onsequent increase in serum insulin that initiate protection.
n the end such nuances become less important when the
odel and the intervention are so clinically pertinent.It is likely that we, as cardiologists, will become more
amiliar with exenatide and the DPP-IV inhibitors as the
sunami of type II diabetes washes over our practice. On the
asis of the study of Timmers et al. (6), it is possible that we
ight have the beginning of a flood defense. There is
ppreciable circumstantial evidence that the incretins and
heir mimetics will reduce cardiovascular risk as well as
mprove outcomes in those with a cardiovascular event.
owever, in the competition to find interventions that
educe reperfusion injury in the clinic, there is only 1
easure that matters: hard clinical end points.
eprint requests and correspondence: Dr. Michael S. Marber,
epartment of Cardiology, Kings College London, The Rayne
nstitute, St Thomas’ Hospital, London SE1 7EH, United King-
om. E-mail: mike.marber@kcl.ac.uk.
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